• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 9
  • 6
  • 2
  • 1
  • 1
  • Tagged with
  • 19
  • 19
  • 19
  • 19
  • 9
  • 9
  • 8
  • 8
  • 7
  • 6
  • 6
  • 6
  • 6
  • 6
  • 5
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

Testing bone cell models responsive to a soluble form of klotho

Bonfitto, Anna 11 1900 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / Fibroblast growth factor-23 (FGF23) is a hormone produced in bone that acts upon the kidney to control blood phosphate and 1,25-(OH)2 vitamin D concentrations. Chronic kidney disease-mineral bone disorder (CKD-MBD) is a major public health problem, affecting 1 in 8 individuals. These patients can have markedly elevated FGF23 at end stage disease which is associated with metabolic bone anomalies, left ventricular hypertrophy, as well as increased mortality (>6-fold). The FGF23 co-receptor αKlotho (αKL) is a membrane-bound protein (mKL) that forms heteromeric complexes with FGF receptors (FGFRs) to initiate intracellular signaling. It also circulates as a cleavage product of mKL (‘cleaved’, or cKL). Previously, a patient with increased plasma cKL from a balanced translocation between chromosomes 9 and 13 in the KLOTHO gene presented with metabolic bone disease and a complex endocrine profile, despite hypophosphatemia. The lack of a reliable cell model in which to study potential FGF23-cKL interactions is a major hurdle for the field of phosphate metabolism. The goal of the present studies was to test and characterize bone cell lines that may respond to FGF23 and/or cKL, permitting study of novel aspects of phosphate handling and control of FGF23 expression. It was confirmed that stable delivery of cKL via AAV2/8 to wild type (WT) and KL-KO mice resulted in highly elevated bone FGF23 mRNA. MC3T3 (mouse) and ROS (rat) osteoblastic cell lines were tested for p-ERK1/2 responses to control FGFs, as well as FGF23 and cKL, alone or in combination. Importantly, both cell lines demonstrated responsiveness to FGF23+cKL only, and not the individual factors. To test responsiveness at the cell level, EGR1 mRNA was tested as an index of FGFR activity and showed modest increases with the same treatments, supporting that other factors may be required for full transcriptional effects. The present studies show that MC3T3 have FGF-dependent signaling capabilities, and that the combination of FGF23+cKL is required for efficient MAPK signaling. These results demonstrated that cKL provision is permissive for efficient FGF23 signaling in bone, and revealed important implications for the regulation of FGF23 and cKL in Mendelian, and common, genetic disorders of phosphate handling and biomineralization.
2

Fibroblast growth factor-23 in canine chronic kidney disease

Harjes, Laura 01 September 2017 (has links)
No description available.
3

Fibroblast growth factor-23 and Klotho in bone/mineral and parathyroid disorders

Krajisnik, Tijana January 2009 (has links)
Fibroblast growth factor-23 (FGF23) is a novel, bone-produced hormone that regulates renal phosphate (Pi) reabsorption and calcitriol metabolism. Disorders of mineral and bone metabolism, such as autosomal dominant hypophosphatemic rickets (ADHR) and hyperostosis-hyperphosphatemia syndrome (HHS), witness the importance of well-balanced serum levels of FGF23. Patients with chronic kidney disease (CKD) are highly morbid due to Pi retention/hyperphosphatemia and calcitriol deficiency, which lead to elevated serum levels of parathyroid hormone (PTH) and secondary hyperparathyroidism (sHPT). As a response to hyperphosphatemia, CKD patients have also remarkably high serum FGF23 levels, which are associated with cardiovascular risk factors and increased mortality in CKD. The overall aim of this dissertation was to discern a possible role of FGF23 in parathyroid biology. Our in vitro experiments on isolated bovine parathyroid cells demonstrate that FGF23 directly and dose-dependently suppresses the PTH production and secretion, while increasing the expression of the 25-hydroxyvitamin D3-activating enzyme 1α-hydroxylase. We investigated possible expressional changes in the FGF23 receptor co-factor Klotho in hyperparathyroid disorders and found that Klotho expression is decreased or absent and inversely correlated to serum calcium (Ca) in adenomas of primary HPT (pHPT). In the hyperplastic parathyroid glands of sHPT, Klotho expression declines in parallel with the kidney function and correlates with the glomerular filtration rate. Moreover, Klotho expression is suppressed by Ca and FGF23, increased by calcitriol, but unaffected by Pi and PTH in vitro. Finally, we identified a novel missense mutation in the gene encoding GALNT3, which is normally involved in the post-translational glycosylation of FGF23, as the cause of aberrant FGF23 processing in a patient with HHS. In summary, we provide evidence for a novel bone/parathyroid axis in which FGF23 functions as a direct, negative regulator of the PTH production. High extracellular Ca is a major determinant of the Klotho expression in pHPT, whereas the Klotho levels in sHPT may be attributed to a combination of the high FGF23 and Ca, and low calcitriol levels associated with CKD. Hence, the decreased Klotho expression in sHPT could explain the concomitantly high FGF23 and PTH levels, as well as the failure of FGF23 to prevent or mitigate the development of sHPT in CKD.
4

FGF23 - a possible Phosphatonin

Marsell, Richard January 2008 (has links)
<p>Human physiology is dependent on an accurate phosphate (Pi) homeostasis. Defective Pi regulation causes hyper- or hypophosphatemia, which are associated with ectopic calcification or impaired bone mineralization, and a shortened life span. Current endocrine models of Pi homeostasis are incomplete. However, studies of acquired and hereditary disorders of Pi homeostasis have revealed new potential Pi regulating hormones, Phosphatonin(s). One of these is fibroblast growth factor-23 (FGF23). FGF23 is produced in bone and is secreted into the circulation. Mutations in FGF23 causes disturbed Pi regulation, without the appropriate counter-regulatory actions of parathyroid hormone or vitamin D. By the generation of FGF23 transgenic mice, which display phenotypic similarities to patients with hypophosphatemic disorders, we show that FGF23 exerts endocrine actions in the kidney and causes osteomalacia. Renal FGF23 actions severely decrease Pi reabsorption and expression of Klotho, a suggested age suppressor gene, known to be crucial in FGF23 receptor binding and activation. In bone, our transgenic model displays impaired osteoclast polarization, which should be detrimental to osteoclastic bone resorption in osteomalacia. However, in our model osteoclasts efficiently participate in bone matrix degradation. Furthermore, we investigated a large population-based cohort in order to elucidate the role of FGF23 in normal physiology. Importantly, we were able to demonstrate an association of FGF23 to parathyroid hormone, renal function and bone mineral density and we found a correlation of FGF23 to weight and body fat mass. The studies on which this thesis is based, demonstrate that FGF23 has phosphatonin-like properties and that the skeleton functions as an endocrine organ. In addition, the results indicate that FGF23 has a role in bone mineral and lipid metabolism, and that FGF23 is a possible diagnostic marker and therapeutic target for the future.</p>
5

Impacto do uso dos quelantes do fósforo, acetato de cálcio e hidrocloreto de sevelamer, sobre os níveis séricos de paratormônio e FGF-23 de pacientes portadores de doença renal crônica / Impact of the use of phosphate binders, calcium acetate or sevelamer hydrochloride, on serum parathormone and FGF-23 levels of chronic kidney disease patients

Oliveira, Rodrigo Bueno de 05 August 2010 (has links)
INTRODUÇÃO: O paratormônio (PTH) e o fator de crescimento de fibroblastos 23 (FGF-23) aumentam precocemente durante o curso da doença renal crônica (DRC) antes do desenvolvimento de hiperfosfatemia. Este estudo avaliou os efeitos de dois quelantes de fósforo, acetato de cálcio (Ca) e hidrocloreto de sevelamer (SEV), nos níveis de PTH e FGF-23 de pacientes com DRC. MÉTODOS: Quarenta e dois pacientes com DRC estágios III e IV foram randomizados em 2 grupos para receber durante 6 semanas, Ca ou Sev. Após este período os pacientes foram seguidos por mais 2 semanas (washout). Analisamos os efeitos destes quelantes sobre os parâmetros do metabolismo ósseo e mineral. RESULTADOS: No início do estudo, os pacientes apresentaram-se com fração de excreção do fósforo, PTH e FGF-23 séricos elevados. Durante o tratamento com quelantes de fósforo houve um declínio progressivo nos níveis de PTH e fósforo urinário, mas sem mudanças nos níveis séricos de cálcio e fósforo. Ocorreu uma mudança significativa nos níveis de FGF-23 no grupo de pacientes tratados com Sev. CONCLUSÕES: Este estudo confirmou os efeitos positivos da prescrição de quelantes de fósforo no controle do PTH, nos estágios III e IV da DRC. Estudos prospectivos e de longo seguimento são necessários para confirmar os efeitos do Sev sobre os níveis de FGF-23 e os benefícios de sua redução sobre parâmetros como mortalidade / INTRODUCTION: Parathyroid hormone (PTH) and fibroblast growth factor (FGF-23) levels increase early in CKD before the occurrence of hyperphosphatemia. This study evaluated the effect of two phosphate binders, calcium carbonate or sevelamer hydrocloride, on PTH and FGF-23 levels in patients with CKD. METHODS: Forty two patients were randomized in two groups to receive calcium acetate or sevelamer hydrochloride, over a 6-wk period. After that, the patients were followed by more two weeks and effects of phosphate binders on mineral parameters were analyzed. RESULTS: At baseline, patients presented with elevated fractional excretion of phosphate, serum PTH and FGF-23 During treatment with both phosphate binders, there was a progressive decline in serum PTH and urinary phosphate, but no change in serum calcium or serum phosphate. Significant changes were observed for FGF-23 only in sevelamer-treated patients. CONCLUSIONS: This study confirms the positive effects of early prescription of phosphate binders on PTH control. Prospective and long-term studies are necessary to confirm the effects of sevelamer hydrocloride on serum FGF-23 and the benefits of this decrease on outcomes
6

FGF23 - a possible Phosphatonin

Marsell, Richard January 2008 (has links)
Human physiology is dependent on an accurate phosphate (Pi) homeostasis. Defective Pi regulation causes hyper- or hypophosphatemia, which are associated with ectopic calcification or impaired bone mineralization, and a shortened life span. Current endocrine models of Pi homeostasis are incomplete. However, studies of acquired and hereditary disorders of Pi homeostasis have revealed new potential Pi regulating hormones, Phosphatonin(s). One of these is fibroblast growth factor-23 (FGF23). FGF23 is produced in bone and is secreted into the circulation. Mutations in FGF23 causes disturbed Pi regulation, without the appropriate counter-regulatory actions of parathyroid hormone or vitamin D. By the generation of FGF23 transgenic mice, which display phenotypic similarities to patients with hypophosphatemic disorders, we show that FGF23 exerts endocrine actions in the kidney and causes osteomalacia. Renal FGF23 actions severely decrease Pi reabsorption and expression of Klotho, a suggested age suppressor gene, known to be crucial in FGF23 receptor binding and activation. In bone, our transgenic model displays impaired osteoclast polarization, which should be detrimental to osteoclastic bone resorption in osteomalacia. However, in our model osteoclasts efficiently participate in bone matrix degradation. Furthermore, we investigated a large population-based cohort in order to elucidate the role of FGF23 in normal physiology. Importantly, we were able to demonstrate an association of FGF23 to parathyroid hormone, renal function and bone mineral density and we found a correlation of FGF23 to weight and body fat mass. The studies on which this thesis is based, demonstrate that FGF23 has phosphatonin-like properties and that the skeleton functions as an endocrine organ. In addition, the results indicate that FGF23 has a role in bone mineral and lipid metabolism, and that FGF23 is a possible diagnostic marker and therapeutic target for the future.
7

Impacto do uso dos quelantes do fósforo, acetato de cálcio e hidrocloreto de sevelamer, sobre os níveis séricos de paratormônio e FGF-23 de pacientes portadores de doença renal crônica / Impact of the use of phosphate binders, calcium acetate or sevelamer hydrochloride, on serum parathormone and FGF-23 levels of chronic kidney disease patients

Rodrigo Bueno de Oliveira 05 August 2010 (has links)
INTRODUÇÃO: O paratormônio (PTH) e o fator de crescimento de fibroblastos 23 (FGF-23) aumentam precocemente durante o curso da doença renal crônica (DRC) antes do desenvolvimento de hiperfosfatemia. Este estudo avaliou os efeitos de dois quelantes de fósforo, acetato de cálcio (Ca) e hidrocloreto de sevelamer (SEV), nos níveis de PTH e FGF-23 de pacientes com DRC. MÉTODOS: Quarenta e dois pacientes com DRC estágios III e IV foram randomizados em 2 grupos para receber durante 6 semanas, Ca ou Sev. Após este período os pacientes foram seguidos por mais 2 semanas (washout). Analisamos os efeitos destes quelantes sobre os parâmetros do metabolismo ósseo e mineral. RESULTADOS: No início do estudo, os pacientes apresentaram-se com fração de excreção do fósforo, PTH e FGF-23 séricos elevados. Durante o tratamento com quelantes de fósforo houve um declínio progressivo nos níveis de PTH e fósforo urinário, mas sem mudanças nos níveis séricos de cálcio e fósforo. Ocorreu uma mudança significativa nos níveis de FGF-23 no grupo de pacientes tratados com Sev. CONCLUSÕES: Este estudo confirmou os efeitos positivos da prescrição de quelantes de fósforo no controle do PTH, nos estágios III e IV da DRC. Estudos prospectivos e de longo seguimento são necessários para confirmar os efeitos do Sev sobre os níveis de FGF-23 e os benefícios de sua redução sobre parâmetros como mortalidade / INTRODUCTION: Parathyroid hormone (PTH) and fibroblast growth factor (FGF-23) levels increase early in CKD before the occurrence of hyperphosphatemia. This study evaluated the effect of two phosphate binders, calcium carbonate or sevelamer hydrocloride, on PTH and FGF-23 levels in patients with CKD. METHODS: Forty two patients were randomized in two groups to receive calcium acetate or sevelamer hydrochloride, over a 6-wk period. After that, the patients were followed by more two weeks and effects of phosphate binders on mineral parameters were analyzed. RESULTS: At baseline, patients presented with elevated fractional excretion of phosphate, serum PTH and FGF-23 During treatment with both phosphate binders, there was a progressive decline in serum PTH and urinary phosphate, but no change in serum calcium or serum phosphate. Significant changes were observed for FGF-23 only in sevelamer-treated patients. CONCLUSIONS: This study confirms the positive effects of early prescription of phosphate binders on PTH control. Prospective and long-term studies are necessary to confirm the effects of sevelamer hydrocloride on serum FGF-23 and the benefits of this decrease on outcomes
8

Participação do fator de crescimento de fibroblastos-23 (FGF-23) no estresse oxidativo, no metabolismo energético, alterações morfológicas e funcionais cardíacas associadas à suplementação de vitamina D em ratos

Figueiredo, Amanda Menezes January 2020 (has links)
Orientador: Sergio A.R. de Paiva / Resumo: A deficiência/insuficiência de vitamina D tem aumentado nos últimos anos e tornou-se problema mundial de saúde pública. Além do raquitismo, a deficiência de vitamina D também está associada com maior risco de desenvolver câncer, doenças imunológicas e, inclusive, doenças cardiovasculares. Estes fatores têm incentivado o uso indiscriminado da suplementação de vitamina D na população saudável. Suplementação de vitamina D, em altas doses, promove estresse oxidativo, inflamação, apoptose, altera o metabolismo energético, morfologia e função cardíaca. Adicionalmente, esta suplementação aumenta a concentração sérica de fósforo, que pode estimular a liberação do fator de crescimento de fibroblasto-23 (FGF-23). Esta maior concentração sérica de FGF-23 pode estar associada à remodelação cardíaca. Outros autores sugerem que a ação do FGF-23 no coração ocorre por meio da via de sinalização calcineurina/fator nuclear das células T ativadas (NFAT). Desta maneira, a menor fosfatemia, promovida pelo uso de sevelamer, poderia atenuar as alterações cardíacas provocadas pela suplementação de vitamina D. Assim, o objetivo deste trabalho é verificar se o tratamento com sevelamer diminui a concentração de FGF-23 e, consequentemente, atenua a remodelação cardíaca, decorrente da suplementação de vitamina colecalciferol, em altas doses. Foram utilizados 169 ratos machos da raça Wistar alocados em seis grupos: 1) Grupo controle alimentado com ração padrão (C, n=27); 2) Grupo controle + 3% de sevelame... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Vitamin D deficiency/insufficiency has increased in recent years and has become a worldwide public health problem. In addition to rickets, vitamin D deficiency is also associated with increased risk of developing cancer, immune diseases and even cardiovascular diseases. These factors have encouraged the indiscriminate use of vitamin D supplementation in the healthy population. High-dose of vitamin D supplementation promotes oxidative stress, inflammation, apoptosis, changes in energy metabolism, morphology and cardiac function. In addition, this supplementation increases the serum phosphorus concentration which can stimulate the release of fibroblast growth factor-23 (FGF-23). Higher serum concentration of FGF-23 can be associated with cardiac remodeling. Other authors suggest that the action of FGF-23 in heart occurs through the signaling pathway calcineurin/nuclear factor of activated T cells (NFAT). Thus, decrease in phosphatemia, promoted by the use of sevelamer, can attenuate the cardiac changes promoted by vitamin D supplementation. The aim of this study is to verify whether treatment with sevelamer decreases the concentration of FGF-23 and, consequently, attenuates cardiac remodeling, due to supplementation of cholecalciferol vitamin, in high doses. 169 male Wistar rats were allocated in six groups: 1) Control group fed standard chow (C, n=27); 2) Control group + 3% sevelamer (C+S, n=26); 3) Group supplemented with 3,000 IU cholecalciferol/kg of chow (VitD 3, n=29); 4)... (Complete abstract click electronic access below) / Doutor
9

Angiopoietin-2 und Fibroblast Growth Factor 23: Prognostische Bedeutung neuer Biomarker im kardiogenen Schock. Eine Substudie der IABP-SHOCK II Studie

Denks, Daniel 06 May 2019 (has links)
Im Rahmen der vorliegenden Dissertation wurde die prognostische Relevanz von Angiopoietin-2 (Ang-2) und Fibroblast Growth Factor 23 (FGF-23) als Prädiktor der 30-Tages sowie Ein-Jahres Mortalität bei Patienten im infarktbedingten kardiogenen Schock (CS) untersucht und dargestellt. Das betrachtete Patientenkollektiv dieser Substudie rekrutierte sich dabei aus den 218, im Rahmen der IABP- SHOCK II Studie in Leipzig eingeschlossenen Patienten. Nach Hospitalisierung und Randomisierung in den jeweiligen Therapiearm (IABP, Nicht-IABP) erfolgte eine prospektiv geplante Blutentnahme an den Tagen eins bis drei. Zur laborchemischen Bestimmung der Serum-, beziehungsweise Plasma Proteinkonzentration mittels ELISA von Ang-2 standen 189, für das Phosphathormon FGF-23 182 Blutproben zur Verfügung. Die 30-Tages Mortalität der untersuchten Substudien-Kohorte betrug 40%, die Ein-Jahres Mortalität 57%. Die vorliegende Arbeit bestätigt Ang-2 als einen starken und unabhängigen negativen Prädiktor des Kurz- und Langzeitverlaufs bei Patienten im CS auf Grund eines akuten Myokardinfarks. Weiterhin zeigt die Auswertung, dass die prognostische Relevanz des betrachteten Biomarkers im zeitlichen Verlauf signifikant zunimmt und verschiedene klinische Parameter wie beispielsweise eine akut eingeschränkte Nierenfunktion oder Blutungskomplikationen unabhängig mit erhöhten Ang-2 Konzentrationen assoziiert sind. Somit sind im infarktbedingten CS hohe Werte von Ang-2 unabhängig mit einem schlechteren klinischen Verlauf des Patienten, sowie dem Reperfusionserfolg und weiteren Komplikationen assoziiert. Patienten der Substudien-Kohorte im infarktbedingten CS waren durch signifikant erhöhte Konzentrationen von FGF-23 charakterisiert. Weiterhin zeigte sich, dass diese signifikant erhöhten Werte unabhängig mit einer deutlich schlechteren Prognose der 30-Tages und Ein-Jahres Mortalität verbunden sind. Diese Assoziation konnte jedoch ausschließlich bei Patienten mit eingeschränkter Nierenfunktion nachgewiesen werden.
10

Avaliação da relação entre metabolismo mineral e doença arterial coronariana em pacientes com função renal preservada / Evaluation of the relationship between mineral metabolism and coronary artery disease in patients with preserved renal function

Cancela, Ana Ludimila Espada 02 September 2011 (has links)
INTRODUÇÃO: Os níveis séricos de fósforo (P) têm sido associados a doenças cardiovasculares e mortalidade em pacientes com doença renal crônica e na população geral. Estudos in vitro demonstram que altas concentrações de fósforo extracellular são capazes de induzir calcificação vascular e disfunção endotelial. O Fibroblast Growth Factor 23 (FGF-23) é um hormônio fosfatúrico e foi relacionado à presença de aterosclerose em pacientes idosos. OBJETIVO: O objetivo deste estudo foi investigar as relações entre P, FGF-23 e outros atores do metabolismo mineral e a ocorrência de doença arterial coronariana em pacientes com função renal preservada. MÉTODOS: Duzentos e noventa pacientes clinicamente estáveis com indicação de cineangiocoronariografia eletiva e clearance de creatinina superior a 60 ml/min/1.73 m2 foram submetidos à Tomografia Computadorizada Multislice para avaliação da calcificação coronariana e coleta de sangue para dosagens bioquímicas. A calcificação coronariana foi quantificada através do Escore de Agatston (EA) e os Escores de Friesinger e Gensini foram calculados para quantificar a obstrução coronariana. RESULTADOS: A média de idade dos pacientes foi 58,1± 9,3 anos, 81% eram hipertensos e 35,5% diabéticos. Os pacientes foram divididos em grupos de acordo com o EA utilizando-se como ponto de corte o valor de 10 Unidades Hounsfield (HU). O P sérico foi maior no grupo de pacientes com EA > 10 HU (3,63 0,55 vs 3,49 0,52mg/dL; p=0,019). Cada 1 mg/dL de elevação no P sérico associou-se a um aumento de 92% no risco de apresentar o EA > 10HU [Odds Ratio (OR) =1,92, CI 1,56-3,19; p=0,01]. Quando os pacientes foram divididos de acordo com a mediana do Escore de Friesinger (4 pontos), o grupo com valores superiores à mediana apresentou P sérico maior (3,6 0,5 vs. 3,5 0,6 mg/dl; p=0,04) e FGF-23 menor (mediana 40,3 pg/mL intervalo interquartil 24,1-62,2 vs. 45,7 pg/mL intervalo interquartil 31,7-76,1; p=0,01) quando comparado àquele com valores menores ou iguais a 4. Pacientes no tercil mais alto do escore de Gensini também apresentaram P sérico mais elevado que os demais (p<0,05). Nas análises de regressão logística uni e multivariadas, cada 1 mg/dL de elevação no P sérico implicou em um aumento de 74% no risco de apresentar o Escore de Friesinger superior à mediana (OR 1,74, CI 1,06- 2,88; p=0,03) e o FGF-23 sérico foi preditor negativo do Escore de Friesinger (OR 0,26, CI 0,11-0,63; p=0,002) Os níveis séricos de cálcio e paratormônio não mostraram associação com a presença de doença coronariana. CONCLUSÃO: Em pacientes com suspeita de doença arterial coronariana e função renal preservada, o fósforo sérico foi preditor da presença de calcificação e obstrução coronariana e houve uma associação negativa entre o FGF-23 sérico e a presença de obstrução coronariana. / INTRODUCTION: Serum phosphorus (P) has been associated with cardiovascular diseases and mortality in chronic kidney disease patients and in the general population. In vitro studies suggest that excessive phosphorus induces vascular calcification and endothelial dysfunction. Fibroblast growth factor 23 (FGF-23) is a phosphaturic hormone and has been correlated to atherosclerosis in the community. AIM: This study intended to investigate the associations between P, FGF-23 and other mineral metabolism players and coronary artery disease in patients with preserved renal function. METHODS: Two-hundred ninety patients with a creatinine clearance higher than 60ml/min/1,73m2 undergoing elective coronary angiography were submitted to Multislice Computed Tomography in order to evaluate coronary calcification and blood was collected for biochemical analyses. Coronary artery calcification was quantified using the Agatston Score (AS). Friesinger (FS) and Gensini Scores (GS) were calcutalet to quantify coronary obstruction. RESULTS: Considering the whole population, mean age was 58.1±9.3 anos, 81% were hypertensive and 35.5% were diabetics. Patients were divided according to AS using the value of 10 Hounsfield Units (HU) as the cutoff.point. Serum phosphorus was higher in patients with an AS > 10HU when compared to the group with an AS 10 HU (3.63 0.55 vs 3.49 0.52mg/dL, p=0.019). Each 1 mg/dL of elevation in the serum phosphorus implied a 92% additional risk of presenting an AS > 10 HU [Odds Ratio (OR) =1.92, CI 1.56-3.19; p=0.01]. Patients were also divided using the median Friesinger score (4 points) as the cutoff value. Serum phosphorus was higher (3.6 0.5 vs. 3.5 0.6 mg/dl, p=0.04) and intact FGF-23 was lower (median 40.3 interquartile range 24.1-62.2 pg/mL vs. 45.7 interquartile range 31.7- 76.1 pg/mL, p=0.01) in the FS > 4 group. Patientis in the higher Gensini Score tertile presented elevated serum phosphorus when compared to the other groups (p<0,05). In the uni and multivariate logistic regression analyses, a rise of 1 mg/dL of serum phosphorus carried a 74% increase in the risk of having a FS higher than 4 (OR 1.74, CI 1.06-2.88; p=0.03) and FGF-23 was a negative predictor of FS (OR 0.26, CI 0.11-0.63; p=0.002). Serum calcium and parathormone were not associated with the presence of coronary artery disease. CONCLUSIONS: In patients with suspected coronary artery disease and preserved renal function, phosphorus was predictive of both coronary artery calcification and obstruction. There was a negative association between FGF-23 and coronary obstruction

Page generated in 0.0922 seconds